Nuceiva receives approval for Australian patients
Medical aesthetic company Evolus has announced that its neurotoxin Nuceiva has received approval for sale in Australia.
Medical aesthetic company Evolus has announced that its neurotoxin Nuceiva has received approval for sale in Australia.
A pilot study of 18 male patients has demonstrated an increase in hair density and thickness following botulinum toxin treatment.
Medical aesthetic company Evolus Inc has announced that the European Commission (EC) has approved the marketing of Nuceiva prabotulinumtoxinA (branded Jeuveau in the US and known in other markets as Nabota).
We bring you the most up-to-date information for the Aesthetics community across a variety of media, including; news, webinars, podcasts, the Journal, reports, interviews and more!
aesthetics Journal
The Aesthetics Journal is the leading monthly publication for the medical aesthetics specialty. It is peer reviewed and spans an incredible volume of topics. Become a member today to receive the monthly print and digital Journal.
0203 096 1228
2nd Floor, Regal House, 70 London Road
Twickenham TW1 3QS, United Kingdom
© 2023 Easyfairs UK Ltd | Registered in England No. 05067979